Lung Cancer Management
Initial Diagnostic Workup
- The American College of Radiology recommends chest CT scanning as the primary imaging modality for patients with suspected lung cancer, providing superior lesion characterization and guiding subsequent diagnostic and staging evaluations 1
- The British Thoracic Society suggests that histological confirmation is mandatory, as sputum cytology alone is insufficient for diagnosis 2, 3
Tissue Acquisition and Pathologic Confirmation
- The British Journal of Cancer recommends obtaining tissue via bronchoscopy for central lesions, or transthoracic needle biopsy for peripheral lesions based on accessibility 1, 2
- For peripheral nodules <2 cm, the British Journal of Cancer suggests transparietal fine needle biopsy as the preferred sampling method 2, 4
Molecular and Biomarker Testing (NSCLC)
- The National Comprehensive Cancer Network recommends comprehensive molecular testing for all patients with advanced NSCLC, including testing for targetable oncogenic alterations: EGFR, ALK, ROS1, BRAF, MET, RET, NTRK 1
- The College of American Pathologists suggests performing PD-L1 expression testing, reported as Tumor Proportion Score for single-agent pembrolizumab decisions or Combined Positive Score for combination regimens 1
Staging Evaluation
- The American Joint Committee on Cancer recommends PET imaging to identify occult metastatic disease, and should be performed in most patients beyond very early-stage disease 1
- The British Journal of Cancer suggests that standard staging workup includes thoracic CT scan, liver ultrasound, brain imaging, and bone imaging, as indicated 5, 1
Treatment by Stage: Non-Small Cell Lung Cancer
- The National Comprehensive Cancer Network recommends surgical resection as the primary and preferred treatment with curative intent for stage I-II NSCLC 7, 1
- The American Society of Clinical Oncology suggests that adjuvant chemotherapy is recommended for stage II NSCLC, and has demonstrated survival benefit 7
Treatment: Small Cell Lung Cancer
- The National Comprehensive Cancer Network recommends first-line platinum-etoposide chemotherapy plus immunotherapy for 4-6 cycles for extensive-stage SCLC 6
- The American Society of Clinical Oncology suggests that brain MRI or CT with contrast is mandatory, as 10-15% of patients have asymptomatic CNS metastases at diagnosis 6
Supportive and Palliative Care Integration
- The American Society of Clinical Oncology recommends introducing palliative care combined with standard oncology care early, at diagnosis rather than when death is imminent, for all patients with stage IV lung cancer and/or high symptom burden 1
- The National Comprehensive Cancer Network suggests performing biopsychosocial assessment soon after diagnosis and at key transition points, and implementing interventions using psychological coping and physical adaptation strategies for breathlessness 1, 2